



ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

Publicly-held Company – CVM Code no. 2612-3

CNPJ/ MF no. 12.104.241/0004-02

Manual for the Extraordinary Shareholders' Meeting of February 28, 2025

CONTENTS

1. Invitation
2. Call Notice
3. Procedures and Terms
4. Information on the Matters on the Agenda
5. Links of Interest

1. INVITATION

Dear Shareholders,

I am pleased to invite you to attend the extraordinary shareholders' meeting of Oncoclínicas do Brasil Serviços Médicos S.A. ("Oncoclínicas" or "Company") to be held at 9:00 a.m., on February 28, 2025 ("ESM"), in the auditorium of the Company's headquarters, located at Avenida Presidente Juscelino Kubitschek, nº 510, CEP 04543-906, in the city and state of São Paulo. If there is quorum for the Meeting to be called to order, you will have the opportunity to discuss and vote on the matters on the agenda, listed in the call notice that is part of item 2 of this Manual.

This Manual contains detailed guidelines for attending the Meeting and should be read together with the management proposal and other documents related to the Meeting, which are available on the Company's Investor Relations website (<https://ri.grupooncoclinicas.com/>), on the website of the Brazilian Securities and Exchange Commission (www.cvm.gov.br), on the website of B3 S.A. – Brasil, Bolsa, Balcão (www.b3.com.br) and at the Company's headquarters.

The Company hopes to continue relying on your support and remains at your disposal for any further clarifications that may be necessary.

Enjoy your reading and the event!

David Castelblanco
Board of Directors Chairman

2. CALL NOTICE

ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

Publicly-held Company – CVM Code no. 2612-3

CNPJ/ MF no. 12.104.241/0004-02

CALL NOTICE EXTRAORDINARY SHAREHOLDERS' MEETING

The Shareholders of **Oncoclínicas do Brasil Serviços Médicos S.A.** (“Company”) are hereby summoned to attend the Extraordinary Shareholders’ Meeting to be held at 9:00 a.m., on February 28, 2025, (“ESM”), at the auditorium of the Company’s headquarters, located at Avenida Presidente Juscelino Kubitschek, nº 510, Vila Nova Conceição, CEP 04543-906, in the city and state of São Paulo, to resolve on the following matters on the agenda:

- (1) approve the “Protocol and Justification for the Merger of Céu de Brasília Participações S.A. by Oncoclínicas do Brasil Serviços Médicos S.A., and Partial Spin-Offs of Cetro – Centro de Tratamento Ltda. and AIO – Instituto de Câncer de Brasília Ltda. with Transfer of Spun-off Net Assets to Oncoclínicas do Brasil Serviços Médicos S.A.” (“Protocol”)
- (2) ratify the appointment and hiring of appraiser Apsis Consultoria e Avaliações Ltda., as the company responsible for preparing the appraisal report on the net assets of Céu de Brasília Participações S.A. (“Céu” and “Céu Appraisal Report”, respectively) and the appraisal reports on the spun-off net assets of Cetro – Centro de Tratamento Ltda. (“Cetro” and “Cetro Appraisal Report”, respectively), and of AIO – Instituto de Câncer de Brasília Ltda. (“AIO” and “AIO Appraisal Report”, respectively), and together with the Céu Appraisal Report and the Cetro Appraisal Report, the “Appraisal Reports”), to be transferred to the Company;
- (3) approve the Appraisal Reports;
- (4) approve the proposed merger of Céu by the Company and partial spin-offs of Cetro and AIO, with the transfer of spun-off net assets to the Company, under the terms and conditions set forth in the Protocol (“Transactions”); and
- (5) authorize the Company’s Board of Executive Officers to perform all acts and measures necessary to implement the Operations.

General Information:

The Management Proposal and the Manual of the Company’s Extraordinary Shareholders' Meeting (“Manual”), containing detailed guidelines for attending the Meeting, as well as all documents pertaining to the matters to be resolved at the Meeting, are available to Shareholders, as of this date, at the Company’s headquarters, on its investor relations website (<https://ri.grupooncoclinicass.com/>), as well as on the websites of the Brazilian Securities and Exchange Commission (www.gov.br/cvm) and B3 S.A. – Brasil, Bolsa, Balcão (www.b3.com.br).

Shareholders may attend the Meeting in person, by a duly appointed proxy or via remote voting form. Detailed information on the documents required can be found in the Manual. Without prejudice to the information presented in the Manual, the Company would like to highlight the following information on the forms to attend the Shareholders' Meeting:

In person: Shareholders who choose to attend the Meeting in person are asked to register by February 26, 2025 (including). Notwithstanding, Shareholders who decide to attend the Meeting in person may do so regardless of whether or not they have registered in advance. Shareholders must present an ID document to attend the Meeting.

By Proxy: Powers of Attorney may be granted in physical form, in compliance with article 126 of Law 6,404/76, as amended, and the Manual. The Shareholder's legal representative must present the power of attorney and other documents indicated in the Manual, as well as an ID document to attend the Meeting.

Via Remote Voting Form: The Company will make available a remote voting system for attending the Meeting, pursuant to CVM Resolution 81/22, as amended ("CVM Resolution 81"), enabling its Shareholders to submit remote voting forms through their respective custody agents or to the bookkeeper of the Company's shares, or even directly to the Company, in accordance with the guidelines set out in the Manual.

The Company will hold the Meeting in person, at its headquarters' auditorium. Pursuant to CVM Resolution 81, Shareholders who attend the Meeting in person or are represented at it, or whose remote voting form has been deemed valid by the Company, will be considered present at the meeting.

For the purposes of article 5, paragraph 4, of CVM Resolution 81, the Company clarifies that holding the Meeting in person aims to preserve the traditional meeting model, which is widely known and adopted by shareholders, ensuring greater predictability and alignment with the Company's institutional practices. Furthermore, the Company believes that holding the Meeting in person provides a more favorable environment for debate and interaction between shareholders and the Company's Management, allowing for more dynamic and efficient communication.

February 6, 2025

David Castelblanco
Board of Directors Chairman

3. PROCEDURES AND TERMS

The Meeting will be called to order on first call, if Shareholders representing at least 1/4 (one-fourth) of total voting rights are present, pursuant to article 125 of Law 6,404/1976, as amended (“Brazilian Corporation Law”). If the quorum of 1/4 (one-fourth) of total voting rights is not reached, the Meeting will not be called to order.

If necessary, the Company will announce a new date for the Meeting, which may be called to order on second call with any number of shareholders in attendance.

Shareholders may participate in person or by duly appointed proxy, as provided for in CVM Resolution 81/22.

3.1. Attendance in Person

The Company will start registering shareholders who wish to attend the Meeting as soon as the call notice is published. Shareholders who choose to attend the Meeting in person are asked to register by February 26, 2025 (including), by sending the necessary documents to “Cristiano Affonso Ferreira de Camargo” - Diretoria de Relações com Investidores - AGE 2025”, at the Company’s headquarters.

If you have any questions, please contact the Company’s Investor Relations Department by e-mail at ri@oncoclinicas.com or by telephone at +55 (11) 2678-7474.

On the day of the Meetings, the Company will begin registering shareholders to attend the Meeting at 08:30 a.m. in the auditorium of the Company’s headquarters. Shareholders who wish to attend the Meetings must present themselves reasonably in advance of the time indicated in the call notice (9:00 a.m.), presenting the following documents, unless they have already been submitted during prior registration:

#	Shareholder	Required documents
1	Individuals	Copy of the shareholder's photo ID. Examples: ID Card (RG), Foreigner’s ID (RNE), Drivers’ License (CNH) or officially recognized professional ID cards.
2	Companies	Copy of the following documents: - consolidated bylaws or most recent articles of association and corporate documents that attest to the shareholder’s legal representation; and - ID card of the legal representative(s), as per item 1 above.
3	Shareholder incorporated as an Investment Fund	Copy of the following documents: - the fund’s most up-to-date consolidated regulation; - the most up-to-date consolidated bylaws or articles of incorporation of the administrator or manager, as the case may be, in accordance with the fund’s voting policy and corporate documents that attest to the representation powers; and - ID card of the legal representative(s), as per item 1 above.

The Company does not require certified signature and/or consular certification or apostille of the powers of attorney granted by the Shareholders to their respective representatives, nor it requires sworn translations of the powers of attorney and documents drawn up or translated into Portuguese or English, nor of the documents attached with the respective translations into these languages.

We would like to emphasize that the request for prior registration is intended to facilitate the preparation of the Meeting and does not represent any obstacle to shareholder participation.

3.2. Shareholder represented by Proxy

Shareholders who cannot attend the Meeting may be represented by a proxy, appointed less than one (1) year prior to the meeting and in accordance with the provisions of paragraph 1, article 126 of the Brazilian Corporation Law.

Pursuant to paragraph 1, article 126 of the Brazilian Corporation Law, proxies may only be granted to those who meet at least one of the following requirements:

- i. to be a Company's shareholder or management member;
- ii. to be an attorney-at-law; or
- iii. to be a financial institution.

For corporate shareholders, there is no need for the proxy to be:

- i. a Company's shareholder or management member;
- ii. an attorney-at-law; or
- iii. a financial institution.

The Company will start registering shareholders represented by proxy as soon as the call notice is published.

Shareholders who choose to be represented by proxy are asked to register by February 26, 2025 (including), by sending the necessary documents to "*Cristiano Affonso Ferreira de Camargo*" - *Diretoria de Relações com Investidores - AGE 2025*", at the Company's headquarters.

If you have any questions, please contact the Company's Investor Relations Department by e-mail at ri@oncoclinicas.com or by telephone at +55 (11) 2678-7474.

On the day of the Meeting, the Company will begin registering shareholders represented by proxy to attend the Meeting at 08:30 a.m. in the auditorium of the Company's headquarters. The shareholder's proxy must present themselves reasonably in advance of the time indicated in the call notice (9:00 a.m.), presenting the following documents, unless they have already been submitted during prior registration:

- i Power of attorney granted by the shareholder to the proxy;
- ii Copy of the proxy's photo ID (Examples: ID Card (RG), Foreigner's ID (RNE), Drivers' License (CNH) or officially recognized professional ID cards issued by Public Administration bodies, provided that they contain a photo of the holder);
- iii Proof of ownership of Company's shares; and
- iv Shareholder's documents listed in the table in item 3.1 above, as the case may be.

We would like to emphasize that the request for prior submission of the power of attorney for shareholders who wish to be represented by duly appointed proxy is intended to facilitate the preparation of the Meeting in the auditorium of the Company's headquarters and does not represent any obstacle to shareholder participation.

3.3. Attendance by Remote Voting Form

Shareholders can also cast their vote at the Meeting by sending in the remote voting form ("Voting Form"), as provided for in CVM Resolution 81. Voting will be formalized through the Voting Form, according to the versions made available by the Company on its Investor Relations website (<https://ri.grupooncoclinicas.com>), on the websites of the CVM (<https://www.gov.br/cvm/pt-br>) and the B3 S.A. - Brasil, Bolsa, Balcão (www.b3.com.br) or through the shareholders' respective custody agents.

The Voting Form must contain the full name (or corporate name, if a legal entity) and the registration number with the Ministry of Economy, either as a legal entity (CNPJ) or as an individual (CPF). We strongly recommend filling in the e-mail address, although it is not mandatory.

In order for the Voting Form to be considered valid and the votes cast on it to be counted as part of the Meeting's quorum (i) all fields must be duly filled in; (ii) all pages must be initialed by the shareholder (or their legal representative, as the case may be); and (iii) at the end, the shareholder (or their legal representative, as the case may be) must sign it. In addition, the shareholder must send, together with the Voting Form, the applicable documents, as described below.

The deadline for receiving the Voting Form sent directly to the Company or through service providers (pursuant to article 27 of CVM Resolution 81) is 4 (four) days prior to the date of the Meeting, that is, February 24, 2025 (including). Voting Forms received after this date will be disregarded.

3.3.1. Attendance by sending Remote Voting Form to service providers

Shareholders who decide to exercise their remote voting rights through service providers must inform their voting instructions to their respective custody agents that provide this service – for shareholders whose shares are held in custody in the central depository – or to BTG Pactual Serviços Financeiros S.A. DTVM ("BTG"), the financial institution responsible for the Company's book-entry share services – for shares that are not held in a central depository – and provided that the rules and deadlines determined by them are observed.

To do so, shareholders should contact their custody agents or BTG, as the case may be, and check the procedures established by them for sending voting instructions via the Voting Form, as well as the documents and information that may be required.

Shareholders must send their voting instructions to their custody agents or to the bookkeeping agent in advance of the date of the Meeting, as set forth by CVM Resolution 81 (i.e. up to four (4) days before the Meeting, that is, by February 24, 2025 (including)).

Said service providers shall inform shareholders of the receipt of voting instructions or the need to rectify or resend them, and shall inform the applicable procedures and terms.

As set forth by CVM Resolution 81, any conflicting voting instructions sent by the same

shareholder through different service providers, as identified by their CPF or CNPJ, will be rejected.

3.3.2. Attendance by sending Remote Voting Form directly to the Company

Shareholders who decide to exercise their voting rights remotely by sending the Voting Form directly to the Company in digital format must send the documents listed below exclusively to the e-mail address ri@oncoclinicas.com. (Subject: “Remote Voting Form 2025 ESM”)

Shareholders who decide to exercise their voting rights remotely by sending the Voting Form directly to the Company in paper format must send the documents listed below to the following address: Avenida Presidente Juscelino Kubitschek, nº 510, 2º Andar, Vila Nova Conceição, in the City of São Paulo, State of São Paulo, CEP 04.543-906”, to the attention of “Diretoria de Relações com Investidores da Companhia - AGE 2025”

The following documents are required: the Voting Form in digital or paper format, duly filled out, initialed and signed; and digital or paper copy of the following documents: (a) individual shareholders: photo ID; (b) corporate shareholders: latest consolidation of the bylaws or articles of association and supporting documents of representation (minutes of executive officers’ election and/or power of attorney) and photo ID of the legal representative(s); and (c) shareholders who are investment funds: the latest consolidated fund regulations, the bylaws or articles of association of its manager and documents attesting to representation powers (minutes of directors’ election and/or power of attorney) and ID document of the legal representative(s).

The Company does not require certified signature, consular certification or apostille of shareholders’ identification documents or powers of attorney granted by shareholders to their respective representatives. The Company does not require sworn translations of the powers of attorney and documents drawn up or translated into Portuguese or English, nor of the documents attached with the respective translations into these languages.

The Voting Form and related documents will only be deemed to have been received by the Company and, therefore, taken into account for the Meeting quorum if the Company receives the digital or paper copies (as the case may be), pursuant to items (i) and (ii) above no later than 4 (four) calendar days before the date on which the Meeting is to be held, i.e. by February 24, 2025 (including). The Voting Form and related documents received after this date will be disregarded.

3.4. Conflict of Interests

During the Meeting, as is the case with the meetings of the Company’s management and oversight bodies, attending shareholders must declare any conflict of interest in any matter under discussion or deliberation, in which their independence may be compromised. Any attending shareholder who is aware of a conflict of interest in relation to another shareholder and the matter being resolved should also speak up.

When a conflict of interest is informed, the conflicted shareholder must abstain from resolving on that matter. If the conflicted shareholder refuses to abstain from the aforementioned resolution, the meeting chairman must order the annulment of the conflicted votes cast, even if after the meeting.

4. INFORMATION ON THE MATTERS ON THE AGENDA

For information on the matters to be resolved at the Meeting, please read the Management Proposal and other related documents, which are available on the Company's Investor Relations website (<https://ri.grupooncoclinicas.com/>), on the website of the Brazilian Securities and Exchange Commission (www.cvm.gov.br), on the website of B3 S.A. – Brasil, Bolsa, Balcão (www.b3.com.br) and at the Company's headquarters.

5. LINKS OF INTEREST

<https://grupooncoclinicas.com/> - Company's website

<https://ri.grupooncoclinicas.com/> - Company's Investor Relations website

www.cvm.gov.br - Law applicable to publicly-held companies and Information on the Company

www.b3.com.br - Novo Mercado Listing Rules